Loading...
Market
Will Wegovy reduce COVID-19 morbidity by 29% in a new clinical trial by Dec 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Results published in a peer-reviewed medical journal or official Novo Nordisk press release
Story
Novo Nordisk's Wegovy with Semaglutide Reduces Heart Failure and COVID-19 Risks by Up to 29%
Aug 30, 2024, 09:14 AM
Novo Nordisk's Wegovy, containing semaglutide, has been shown to reduce the risk of severe complications in patients with a common form of heart failure, according to a new analysis. Research indicates that semaglutide, found in both Ozempic and Wegovy, can decrease the risk of heart failure events and cardiovascular death by up to 29%. A study involving 3,533 diabetic patients highlighted a 27% lower risk of heart-related complications. Additionally, a Harvard study suggests that these medications also reduce the risk of severe COVID-19 in individuals with obesity. The SELECT trial further supports these findings, showing reduced COVID-19-associated morbidity and mortality.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Yes • 50%
No • 50%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
